Pranlukast, a Cysteinyl Leukotriene Antagonist, Reduces Serum Eosinophil Cationic Protein Levels in Patients with Asthma

アクセス数 : 1072
ダウンロード数 : 142

今月のアクセス数 : 2
今月のダウンロード数 : 1
File
HiroshimaJMedSci_48_105.pdf 670 KB 種類 : fulltext
Title ( eng )
Pranlukast, a Cysteinyl Leukotriene Antagonist, Reduces Serum Eosinophil Cationic Protein Levels in Patients with Asthma
Creator
Ishioka Shinichi
Hozawa Soichiro
Hiyama Keiko
Maeda Akihiro
Yamakido Michio
Source Title
Hiroshima Journal of Medical Sciences
Volume 48
Issue 4
Start Page 105
End Page 110
Journal Identifire
[PISSN] 0018-2052
[EISSN] 2433-7668
[NCID] AA00664312
Abstract
Cysteinyl leukotrienes (cysLTs) are considered to be important mediators involved in bronchial asthma and the ensuing eosinophilic inflammation. We evaluated the effects of pranlukast, a potent and selective cysLT receptor antagonist, on the clinical course and serum eosinophil cationic protein (ECP) levels of 10 asthmatic patients. A four-week administration of pranlukast increased the morning peak expiratory flow (PEF) (p=0.007) and decreased as-needed /3z-agonist use (p=0.021). Changes in the morning PEF inversely correlated with those in the serum ECP levels (r=-0.80, p=0.0057). These results suggest that cysLTs are important mediators involved in eosinophilic inflammation, a major pathophysiologic feature of bronchial asthma in humans.
Keywords
Bronchial asthma
Cysteinyl leukotriene receptor antagonist
Pranlukast
Serum eosinophil cationic protein
Descriptions
Part of this study was supported by a research grant from the Japanese Ministry of Health and Welfare.
NDC
Medical sciences [ 490 ]
Language
eng
Resource Type departmental bulletin paper
Publisher
Hiroshima University Medical Press
Date of Issued 1999-12
Publish Type Version of Record
Access Rights open access
Source Identifier
[ISSN] 0018-2052
[NCID] AA00664312